Abstract
Papaverine, 150 mg BID for 2 weeks, a dose which produced marked clinical impairment in Parkinsonian patients taking L-Dopa, failed to alter L-Dopa-stimulated GH secretion or L-Dopa inhibited PRL secretion in 6 normal volunteers. Failure to demonstrate an inhibitory effect of papaverine on dopaminergic hypothalamic-pituitary systems, despite its inhibition of striatal dopaminergic pathways, may imply qualitative or quantitative functional differences between hypothalamic and striatal dopaminergic systems.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.